Transaction

NetReveal Enhancements Help Close the Gap Between Evolving Digital Risk and Compliance

Friday, September 24, 2021 - 9:00am

BAE Systems Applied Intelligence is adding market leading enhancements to its NetReveal Compliance Solution Suite to help organisations remain compliant in the complex and evolving money laundering and terrorist finance ecosystem.

Key Points: 
  • BAE Systems Applied Intelligence is adding market leading enhancements to its NetReveal Compliance Solution Suite to help organisations remain compliant in the complex and evolving money laundering and terrorist finance ecosystem.
  • Our expertise in protecting financial institutions against changing threats lies in understanding criminal threats and risk regardless of the format, entity or industry, said Peter Fisher, Product Director for Financial Services.
  • As compliance moves to encompass evolving digital criminality, we use connected data and collaboration to help banks address their ever-expanding remit of responsibility.
  • The latest enhancements in NetReveal encompass both product-based adaptability to augment existing compliance solutions and features to help organisations ensure compliance in an evolving criminal and regulatory landscape.

WPT Industrial Real Estate Investment Trust Announces Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Unitholders Vote FOR the Proposed Transaction with Blackstone Real Estate Income Trust

Friday, September 24, 2021 - 12:18am

ISS and Glass Lewis are leading independent proxy advisory firms that provide voting recommendations to institutional investors.

Key Points: 
  • ISS and Glass Lewis are leading independent proxy advisory firms that provide voting recommendations to institutional investors.
  • Enter the 16-digit control number printed on the voting instruction form and follow the instructions on screen.
  • Fax: Complete, date, and sign the voting instruction form and fax it to the number listed on the voting instruction form.
  • WPT Industrial Real Estate Investment Trust is an unincorporated, open-ended real estate investment trust established pursuant to a declaration of trust under the laws of the Province of Ontario.

Endocan Announces Closing of Financing

Thursday, September 23, 2021 - 9:08pm

Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - Endocan Solutions Inc. ("Endocan" or the "Company") announces that it has completed a non-brokered private placement of 1,914,529 shares at a price of $0.35 per share for net proceeds of $670,085.00.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 23, 2021) - Endocan Solutions Inc. ("Endocan" or the "Company") announces that it has completed a non-brokered private placement of 1,914,529 shares at a price of $0.35 per share for net proceeds of $670,085.00.
  • The Company will use the net proceeds from the Financing to fund operations.
  • The Shares issued will be subject to a statutory four month hold period.
  • Endocan Solutions Inc. is a Reporting Issuer that has recently undergone recapitalization and reorganization.

Strategic Alliance with Ross Lifescience Opens the Way for Potential Fast Commercialisation of Forrest's Natural Vector Control in India

Tuesday, September 21, 2021 - 2:00pm

Ross conducts laboratory as well as field trials for evaluating the efficacy of various products to control insect pests.

Key Points: 
  • Ross conducts laboratory as well as field trials for evaluating the efficacy of various products to control insect pests.
  • Under the Public health activities, Ross conducts multi-location field trials to test the efficacy of products.
  • Ross also produces and markets products in the mosquito-transmitted disease sector and has extensive distribution expertise throughout India.
  • Forrest's proprietary technology, Natural Vector Control (NVC), is commercially approved.

Cresco Labs to Acquire Three High-Performing Pennsylvania Dispensaries

Thursday, September 23, 2021 - 12:30pm

Were thrilled to continue executing our playbook of achieving depth in strategic markets via rigorous capital allocation, said Charlie Bachtell, CEO and Co-Founder of Cresco Labs.

Key Points: 
  • Were thrilled to continue executing our playbook of achieving depth in strategic markets via rigorous capital allocation, said Charlie Bachtell, CEO and Co-Founder of Cresco Labs.
  • The Cure Penn team has developed a high-performing retail platform across three dispensaries that sets up another immediately accretive acquisition for Cresco Labs.
  • Three operational Cure Penn dispensaries in Lancaster, Phoenixville, and Philadelphia
    A retail platform that outperforms the average revenues per-store in Pennsylvania.
  • Sunnyside, Cresco Labs national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers.

McDermott Extends Hiring Spree with Six New Transactions Partners

Thursday, September 23, 2021 - 2:06pm

"We're in the midst of a hiring boom, and this new group is in addition to firepower added this year99 lawyers globally just in the Transactions group itself."

Key Points: 
  • "We're in the midst of a hiring boom, and this new group is in addition to firepower added this year99 lawyers globally just in the Transactions group itself."
  • She also represents lenders in the purchase, workout and restructuring of distressed loans, debt and equity financing and other intercreditor transactions.
  • Andy Lehman (Houston) advises clients in complex mergers and acquisitions (M&A), joint ventures, structured equity transactions and management equity arrangements.
  • McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets.

Valley National Bancorp to Acquire Bank Leumi USA Creating a Premier Commercial Bank With Unique, Sustainable and Diverse Growth Opportunities

Thursday, September 23, 2021 - 11:40am

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Valley National Bancorp (Valley) (NASDAQ: VLY) and Bank Leumi Le-Israel Corporation (Leumi) announced today that they have entered into a definitive merger agreement whereby Valley will acquire Leumi, the US subsidiary of Bank Leumi Le-Israel B.M., and parent company of Bank Leumi USA (Bank Leumi).

Key Points: 
  • NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Valley National Bancorp (Valley) (NASDAQ: VLY) and Bank Leumi Le-Israel Corporation (Leumi) announced today that they have entered into a definitive merger agreement whereby Valley will acquire Leumi, the US subsidiary of Bank Leumi Le-Israel B.M., and parent company of Bank Leumi USA (Bank Leumi).
  • Bank Leumis fee income is primarily driven by cash management services for commercial customers, and investment management fees within Bank Leumis private bank.
  • As the principal subsidiary of Valley National Bancorp, Valley National Bank is a regional bank with approximately $41 billion in assets as of June 30, 2021.
  • Bank Leumi Le-Israel Corporation is the U.S.-based holding company for Bank Leumi USA, a New York state chartered bank offering a full range of commercial loan and deposit products.

Inter Pipeline and Brookfield Infrastructure Provide Update on Strategic Transaction and Executive Transition Plan

Thursday, September 23, 2021 - 1:45am

The Circular has been filed on Inter Pipeline's profile on SEDAR at www.sedar.com and is available on Inter Pipeline's website at www.interpipeline.com.

Key Points: 
  • The Circular has been filed on Inter Pipeline's profile on SEDAR at www.sedar.com and is available on Inter Pipeline's website at www.interpipeline.com.
  • Brookfield Infrastructure may vote the Common Shares acquired by it under its takeover bid of Inter Pipeline, which was completed on September 3, 2021, as part of the "minority" approval.
  • Mr. Bayle will also resign from the Board of Directors (the "Board") of Inter Pipeline effective the same day.
  • As part of the Executive Transition Plan, effective September 21, 2021, Mr. Hawksworth was appointed Deputy Chief Financial Officer of Inter Pipeline.

Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd

Wednesday, September 22, 2021 - 12:00pm

Oxford, UK 22 September, 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Serum Life Sciences Ltd (SLS), a subsidiary company of Serum Institute of India Pvt Ltd (Serum Institute of India), has agreed to invest just over 50 million in the Group in return for new ordinary shares representing 3.9% of the outstanding shares after the capital increase (the Transaction).

Key Points: 
  • Oxford, UK 22 September, 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Serum Life Sciences Ltd (SLS), a subsidiary company of Serum Institute of India Pvt Ltd (Serum Institute of India), has agreed to invest just over 50 million in the Group in return for new ordinary shares representing 3.9% of the outstanding shares after the capital increase (the Transaction).
  • John Dawson, Chief Executive Officer of Oxford Biomedica, said: We are delighted that Serum Life Sciences Ltd, a subsidiary company of Serum Institute of India, has made this strategic investment into Oxford Biomedica.
  • Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com
    Serum Life Sciences Ltd is a subsidiary company of Serum Institute of India Pvt Ltd. Its global sales office in London will market COVID-19 vaccines manufactured by Serum Institute of India Pvt Ltd (SII).
  • Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases.

FSD Pharma Announces Closing of Lucid Psycheceuticals Acquisition

Tuesday, September 21, 2021 - 2:47pm

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (Lucid), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately CAD$11.3 million (US$8.9 million) in FSD Pharma stock (the Transaction).

Key Points: 
  • FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (FSD Pharma or the Company), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce the completion of the previously announced acquisition of 100% of the issued and outstanding shares of Lucid Psycheceuticals Inc. (Lucid), a Canadian-based specialty psychedelic pharmaceutical company focused on the development of therapies to treat critical neurodegenerative diseases, for approximately CAD$11.3 million (US$8.9 million) in FSD Pharma stock (the Transaction).
  • The acquisition of Lucid represents a positive and exciting step in pursuit of our strategic objectives at FSD Pharma, as we advance a diversified pipeline of novel, patent-protected drug candidates.
  • Congratulations to Lucid and FSD Pharma on taking this important step to accelerate potential treatment options for patients with multiple sclerosis based on technology developed at UHN.
  • FSD Pharma is a life sciences holding company dedicated to building a portfolio of diversified therapeutic assets and innovative healthcare and biotech services.